| Non-Controlling Interests |
12. Non-Controlling Interests
Non-controlling interests in consolidated entities are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended |
|
|
|
|
|
|
|
|
As of December 31, 2020 |
|
December 31, 2020 |
|
As of December 31, 2020 |
|
|
|
|
|
|
|
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
NCI equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
Acquisition Corp VIII |
|
$ |
(7) |
|
$ |
(27) |
|
$ |
(34) |
|
10.0 |
% |
Aevitas |
|
|
(2,370) |
|
|
(823) |
|
|
(3,193) |
|
39.0 |
% |
Avenue 2 |
|
|
5,800 |
|
|
(3,974) |
|
|
1,826 |
|
77.4 |
% |
Baergic |
|
|
(1,662) |
|
|
(97) |
|
|
(1,759) |
|
39.5 |
% |
Cellvation |
|
|
(1,089) |
|
|
(182) |
|
|
(1,271) |
|
22.1 |
% |
Checkpoint 1 |
|
|
41,704 |
|
|
(13,265) |
|
|
28,439 |
|
80.4 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
567 |
|
|
(1,478) |
|
|
(911) |
|
30.5 |
% |
Helocyte |
|
|
(4,986) |
|
|
(259) |
|
|
(5,245) |
|
18.8 |
% |
JMC |
|
|
138 |
|
|
491 |
|
|
629 |
|
7.1 |
% |
Mustang 2 |
|
|
116,060 |
|
|
(36,429) |
|
|
79,631 |
|
80.9 |
% |
Oncogenuity |
|
|
(82) |
|
|
(376) |
|
|
(458) |
|
25.3 |
% |
Tamid |
|
|
(663) |
|
|
(40) |
|
|
(703) |
|
22.8 |
% |
Total |
|
$ |
153,120 |
|
$ |
(56,459) |
|
$ |
96,661 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended |
|
|
|
|
|
|
|
|
As of December 31, 2019 |
|
December 31, 2019 |
|
As of December 31, 2019 |
|
|
|
|
|
|
|
|
Net loss attributable to |
|
Non-controlling interests |
|
Non-controlling |
|
($ in thousands) |
|
NCI equity share |
|
non-controlling interests |
|
in consolidated entities |
|
ownership |
|
Aevitas |
|
$ |
(1,249) |
|
$ |
(694) |
|
$ |
(1,943) |
|
35.8 |
% |
Avenue 2 |
|
|
24,269 |
|
|
(19,011) |
|
|
5,258 |
|
77.3 |
% |
Baergic |
|
|
23 |
|
|
(1,162) |
|
|
(1,139) |
|
33.0 |
% |
Cellvation |
|
|
(732) |
|
|
(158) |
|
|
(890) |
|
20.6 |
% |
Checkpoint 1 |
|
|
29,389 |
|
|
(14,687) |
|
|
14,702 |
|
78.0 |
% |
Coronado SO |
|
|
(290) |
|
|
— |
|
|
(290) |
|
13.0 |
% |
Cyprium |
|
|
(320) |
|
|
(99) |
|
|
(419) |
|
10.6 |
% |
Helocyte |
|
|
(4,322) |
|
|
(402) |
|
|
(4,724) |
|
19.3 |
% |
JMC |
|
|
(211) |
|
|
325 |
|
|
114 |
|
6.9 |
% |
Mustang 2 |
|
|
62,025 |
|
|
(25,727) |
|
|
36,298 |
|
70.3 |
% |
Tamid |
|
|
(565) |
|
|
(85) |
|
|
(650) |
|
22.8 |
% |
Total |
|
$ |
108,017 |
|
$ |
(61,700) |
|
$ |
46,317 |
|
|
|
Note 1: Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.
Note 2: Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.
|